The European human biospecimen market is projected to grow at an 8.24% CAGR from $881.8 million in 2025 to $1.94 billion by 2035, driven by increasing demand for precision medicine, oncology research, and expanding biobanks. Growth is supported by rising pharmaceutical R&D spending and EU-funded initiatives, though challenges include stringent GDPR regulations, high operational costs, and variability in consent frameworks across countries.

The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.

The global botulinum toxin in urology market is projected to grow from USD 1.1 billion in 2025 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is driven by increasing prevalence of urological disorders, aging populations, preference for minimally invasive treatments, and advancements in injection techniques. OnabotulinumtoxinA (Botox) leads the market, with overactive bladder being the largest application segment.

The hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market share, with approximately 210,000 prevalent cases across the 7MM in 2025.

Canadian health care advocates are calling for the closure of Grifols plasma collection facilities and a public takeover following two deaths in Winnipeg linked to plasma sales, a third lawsuit for kidney damage, and Health Canada reports of non-compliance at four additional Grifols sites.

Pegasys market is poised for significant growth driven by rising hepatitis B prevalence, increasing healthcare spending, and expansion into oncology and hematology indications. However, the market faces headwinds from the rise of direct-acting antivirals and tariff-related cost pressures. North America leads in market share while Asia-Pacific is expected to grow fastest.

The global Plasbumin-5 market is experiencing significant growth driven by rising surgical procedures, burn injuries, and expanding critical care infrastructure. North America leads the market while Asia-Pacific is the fastest-growing region. Grifols Therapeutics, the key market player, has strengthened its position through strategic partnerships, including a December 2023 collaboration with Haier Group to enhance distribution in China. Market growth is supported by innovations in plasma fractionation technologies and increased adoption in liver and cardiac care.

The global blood plasma derivatives market is expected to double from $52.16 billion in 2025 to $104.30 billion by 2033, growing at a 9.08% CAGR. Growth is driven by increasing immune deficiencies, hematological disorders, and neurological conditions, with immunoglobulins representing 41.28% of the market. North America leads with 39.57% market share, while Asia-Pacific is the fastest-growing region at 10.89% CAGR.

The global plasma derived medicine market is projected to grow from $17.24 billion in 2024 to $37.4 billion by 2034, driven by increasing demand for therapies treating rare and immune disorders, with North America currently dominating the market.

The report examines the trends shaping the orphan designated drugs market, including healthcare, technology, macroeconomic, and regulatory factors. It provides insights into leading players and future challengers across the value chain, as well as key drugs and markets.

The global intravenous solutions market is projected to grow at a CAGR of 8.0% from 2024 to 2031, driven by the increasing elderly population, rising rates of chronic diseases, and advancements in medical technology.

The global infectious disease diagnostics market is projected to reach $43.09 billion by 2031, growing at a CAGR of 8.20% during the forecast period. The market is driven by advancements in diagnostic technologies, rising cases of infectious diseases, and increased R&D funding.